Salud financiera de hoja de balance de Alphamab Oncology
Salud financiera controles de criterios 5/6
Alphamab Oncology has a total shareholder equity of CN¥1.6B and total debt of CN¥320.0M, which brings its debt-to-equity ratio to 19.6%. Its total assets and total liabilities are CN¥2.1B and CN¥513.3M respectively.
Información clave
19.6%
Ratio deuda-patrimonio
CN¥320.00m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | CN¥1.46b |
| Patrimonio | CN¥1.63b |
| Total pasivo | CN¥513.25m |
| Activos totales | CN¥2.14b |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: 9966's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥345.4M).
Pasivo a largo plazo: 9966's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥167.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 9966 has more cash than its total debt.
Reducción de la deuda: 9966 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: 9966 has sufficient cash runway for more than 3 years based on its current free cash flow.
Pronóstico de cash runway: Insufficient data to determine if 9966 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.